Fresenius Kabi Breaks Into Brazilian Biosimilars Market

Strikes State-Private Adalimumab Deal With Fiocruz/Bio-Manguinhos And Bionovis

 
• By Rosalind Rei

Fresenius Kabi has struck a deal with Brazilian organizations Fiocruz/Bio-Manguinhos and Bionovis to supply its Idacio biosimilar adalimumab rival to Humira for the next ten years.

Brazil health ministry sign
Fresenius’ Idacio will be the company’s first biosimilar on the Brazilian market • Source: Shutterstock

More from Deals

More from Business